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immunoevolution of mouse 
pancreatic organoid isografts from 
preinvasive to metastatic disease
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pancreatic ductal adenocarcinoma (pDA) has a highly immunosuppressive microenvironment, which 
is contributed by the complex interaction between cancer cells and a heterogeneous population 
of stromal cells. therefore, facile and trackable models are needed for integrative and dynamic 
interrogation of cancer-stroma interaction. Here, we tracked the immunoevolution of pDA in a 
genetically-defined transplantable model of mouse pancreatic tumour organoids that recapitulates the 
progression of the disease from early preinvasive lesions to metastatic carcinomas. We demonstrated 
that organoid-derived isografts (oDi) can be used as a biological source of biomarkers (NT5E, TGFB1, 
FN1, and ITGA5) of aggressive molecular subtypes of human PDA. In ODI, infiltration from leukocytes 
is an early event during progression of the disease as observed for autochthonous models. neoplastic 
progression was associated to accumulation of Maf+ macrophages, which inversely correlated 
with CD8+ T cells infiltration. Consistently, levels of MAF were enriched in human pDA subtypes 
characterized by abundance of macrophage-related transcripts and indicated poor patients’ survival. 
Density of MAf+ macrophages was higher in human pDA tissues compared to preinvasive lesions. our 
results suggest that oDis represent a suitable system for genotypic-immunophenotypic studies and 
support the hypothesis of MAf+ macrophages as a prominent immunosuppressive population in pDA.
Pancreatic ductal adenocarcinoma (PDA) is a deadly disease with a 5-year survival rate less than 6% due to 
late diagnosis and poor responsiveness to available therapies1. Although being the tenth in incidence, PDA is 
the fourth leading cause of cancer death, and it is estimated to become the 2nd cause of cancer deaths within a 
decade2. Differently from other solid tumours3,4, immunotherapeutic strategies have proven ineffective in the 
majority PDA, with the exception being patients with high microsatellite instability5. Many factors contribute to 
the creation of a highly immunosuppressive microenvironment that limit cancer immunotherapy efficacy (e.g., 
immune-checkpoint inhibitors), including poor tumours immunogenicity, a heterogeneous and complex tumour 
microenvironment, and plasticity of PDA cells.
A recent transcriptomic analysis of primary PDA has identified 4 molecular subtypes (ADEX, Pancreatic 
Progenitor, Squamous, and Immunogenic)6, which expanded the previous two-group classification (Basal-like 
and Classical) proposed by Moffit et al.7. Based on intrinsic characteristics of neoplastic cells, PDA can be reliably 
classified as Squamous/Basal-like or Classical/Pancreatic Progenitor, whereas ADEX and Immunogenic subtype 
appear to be driven by transcripts from non-neoplastic cells8. Moreover, these tumour subtypes show different 
prognosis and different response to therapy7,9. Of the four subtypes, two are enriched for immune-related sig-
natures: Immunogenic and Squamous6. The Squamous subtype, which is enriched for squamous and poorly 
differentiated cancers, carries the poorest prognosis and shows signatures indicative of an immune suppressive 
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microenvironment, including elevated macrophage gene expression programs6. Recent studies have shown that 
it is possible to induce a “class switch” from Squamous to more differentiated and more immunogenic subtypes 
by targeting either cancer cell features10 or selected immune populations11,12. It is also becoming clear that cancer 
cell programs driven by specific genetic events are able to dictate the immune landscape of cancers13, includ-
ing PDA14. Therefore, an integrated analysis of genetic features and immunophenotypes is required to identify 
undisclosed immunotherapeutic opportunity in PDA. This possibility has been limited, at least in part, by the 
difficulty in creating complex preclinical models for easy and rapid testing of genotype-driven immunological 
changes. Genetically engineered mouse models (GEMMs) of PDA have demonstrated to faithfully recapitulate 
major pathophysiological features of the human disease, including the prominent stromal reaction that also 
involves immune cells15,16. An alternative approach might be to introduce specific genetic alteration ex vivo and 
then exploit syngeneic cell transplants. However, preclinical mouse models generated through implantation of 
syngeneic monolayer cell cultures cannot be used to track the changes in the immune microenvironment during 
progression from early preinvasive lesions to invasive and metastatic carcinomas. Moreover, cell line-based trans-
plants often fail to produce the fibroinflammatory reaction that characterize the majority of PDA17,18. Recently, 
it has been shown that orthotopic transplants of pancreatic tumour organoid slowly progress from preinvasive 
lesions to invasive carcinoma17. Similar to GEMM, organoid derived isografts recapitulate some of the relevant 
features of human PDA including vascularization and stromal deposition17. Nonetheless, whether and how dis-
ease progression in organoid-derived isografts (ODI) is associated to accumulation of genetic alterations as well 
as to changes in the immune contexture is currently unknown, thus limiting the usefulness of this system for 
translational studies. Here, we characterized the cellular components and the dynamic changes of the immune 
contexture during progression of pancreatic tumour organoid derived isografts.
Results
Histopathological evolution of organoid derived isografts. Using established procedures17,19, we 
generated organoid cultures from the pancreata of wild-type C57Bl/6 mice (n = 3) and from pancreatic tissues 
of KPC (Kras+/LSL-G12D; Trp53+/LSL-R172H; Pdx1-Cre)16 mice (n = 3), which contained invasive PDA (Fig. S1a). 
Although indistinguishable at microscopic evaluation (Fig. S1b), normal- and tumour-derived cultures were 
genetically different. Targeting sequencing of PDA driver genes (19 genes, Table S1) identified mutations of Kras 
and Trp53 in tumour derived organoids (B6-Ks), thereby confirming that these two events are sufficient for the 
development of PDA in mice and are maintained in culture16. As expected, normal organoid cultures (B6-Ns) 
were devoid of mutations in the cancer genes analysed (Fig. S1c).
It has been previously demonstrated that orthotopic transplants of mouse tumour organoids in syngeneic 
immunocompetent mice slowly progress from preinvasive lesions (PanIN-like lesions) to invasive carcinomas17. 
Nonetheless, whether and how disease progression in organoid-derived isografts (ODIs) is associated to accumu-
lation of genetic alterations as well as to changes in the immune contexture is currently unknown.
To evaluate the histopathological progression of organoid derived isografts, we generated an array of 30 ODIs 
from 3 individual organoid cultures (Fig. S1d). The growth of ODIs was monitored using high-contrast ultra-
sonography, which revealed that organoid transplants initially grew as small solid lesions developing from a cystic 
structure, recognizable as spherical black regions with distinct borders (Fig. 1a). Over long period of time (from 1 
to 6 months), the cyst eventually reduced in size. First, we analysed the histological features of tumours from ODI 
at early (1–2 months), intermediate (3–4 months), or late (5–6 months) time points following transplantation. 
Initially, the majority of ODIs developed low- to high-grade preinvasive lesions that cytoarchitecturally resem-
bled mouse PanIN including an abundant deposition of stroma. Over time (3 to 4 months post transplantation), 
ODIs progressed into “classical” mouse PDA, which encompassed well- and moderately differentiated tumours 
with prominent stromal deposition. At later time points (5 to 6 months post transplantation), ODIs were mostly 
poorly differentiated carcinomas (PDC) containing areas with sarcomatoid features and almost no stroma depo-
sition (Figs 1a,b, S1e,f). At any of the time points considered, PDC were the only ODI to present with metastases 
at the liver and the lungs (Fig. 1c). To ask whether this histological progression was associated to accumulation of 
alterations in PDA genes, we applied targeted sequencing of 19 genes to lesions from ODI and found that, except 
for loss of the wild-type copy of Trp53 in PDC, no other genetic alteration accumulated in vivo (Fig. 1d). Loss of 
heterozygosity of Trp53 in metastatic PDC is consistent with previous observations made in the KPC model16.
immunological evolution of organoid derived isografts. To address whether progression of ODI was 
associated to changes in the immune landscape, we applied a multidimensional tumour profiling approach to 
whole pancreatic lesions from ODI sacrificed at different times post transplantation as previously indicated. First, 
we analysed the composition of immune populations by cytofluorimetric analysis. We found substantial changes 
in the total number (Fig. 2a) and relative composition (Fig. 2b) of leukocytes (CD45+ cells) in pancreatic tissues 
from mice bearing lesions at different stages of disease. In the pancreata containing preinvasive lesions and clas-
sical tumours, CD45+ cells represented the 51.7 ± 13.06% and 37.2 ± 9.24% of total cells, respectively, whereas a 
substantial decrease in total leukocytes was observed in PDC (19.50 ± 8.6%) (Fig. S2a). As previously shown in 
KPC mice15, the increased infiltration of leukocytes compared to normal pancreas was associated to the reduction 
of CD45 expressing cells in the spleen of mice bearing pancreatic lesions compared to lesion-free mice suggesting 
an enforced recruitment of leukocytes from lymphoid tissue to the tumour mass (Fig. S2b).
Using established markers of immune cell populations, we found that granulocytes (CD11b+Ly6G+) and 
macrophages (CD11b+F4/80+cells) heavily infiltrated preinvasive lesions and persisted throughout tumour pro-
gression (Figs 2c and S2c). When looking at the relative composition of the CD45+ cells infiltrating ODIs, the 
myeloid populations significantly expanded during progression (Figs 2d and S2d). High density of lymphocytes, 
in particular of CD8+ T cells, has been associated to long-term PDA survivors20. Therefore, we sought to assess 
the degree of infiltrating lymphocytes in our ODI and found a dramatic reduction of T lymphocytes (CD3+cells), 
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TH CD4+ T cells, and particularly of cytotoxic CD8+ T cells, in tumours compared to preinvasive lesions (Fig. 2e). 
In keeping with this, CD8+ T cells were the lymphocytic population to more dramatically reduce during pro-
gression, both in classical tumours and PDC, when looking at relative composition of CD45+ infiltrating cells 
Figure 1. Histopathological evolution of tumour organoid isografts. (a) The growth of tumour organoid 
isografts was monitored by high-contrast ultrasonography (top); tumours are outlined in red. Representative 
hematoxylin & eosin staining (middle) of tissues from a preinvasive lesion, a moderately differentiated 
tumour (classical), and a poorly differentiated carcinoma (PDC) obtained at 1, 3, and 5 months, respectively, 
from orthotopic transplantation of B6-K1 mouse organoids. Scale bars, 100 µm unless otherwise indicated. 
Magnification of selected areas (dashed lines) is provided in the insets. Preinvasive lesions presented an intense 
desmoplastic reaction compared to moderately and poorly differentiated tumours by Masson’s trichrome 
staining (bottom). Scale bars, 100 µm unless otherwise indicated. (b) Bar graph showing the number and type 
of lesions observed in the pancreas of immunocompetent mice at different times from transplantation (m, 
months). (c) Representative metastatic growths at the liver (left) and at the lungs (right) from a mouse bearing 
a poorly differentiated carcinoma (B6-K2 organoid, 3 months from transplantation). The dashed lines indicate 
the areas shown in the insets. Scale bar, 700 µm; insets, 100 µm. (d) Targeted sequencing of preinvasive (n = 3), 
classical tumours (n = 3), and poorly differentiated carcinomas (n = 3) derived from mouse B6-Ks orthotopic 
transplants. The status of the 4 more commonly mutated PDA genes is shown with colour key providing 
information on type of alteration. LOH, loss of heterozygosity. See also Supplementary Fig. S1.
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Figure 2. The composition of immune infiltrates in tumour organoid derived isografts. (a) Pie charts 
showing percentages of granulocytes (CD45+CD11b+Ly6G+), macrophages (CD45+CD11b+F4/80+), B cells 
(CD45+B220+), cytotoxic T cells (CD45+CD3+CD8+), and T helper lymphocytes (CD45+CD3+CD4+) in 
the pancreatic tissues from mice at 2 months (left), 4 months (middle) and 6 months (right) from organoid 
transplantation. “Unstained” denotes pancreatic epithelial cells and other stromal components. Colour key is 
provided. (b) Pie charts showing the immune cell populations defined in (a) as percentages of CD45+ cells. 
Colour key as in (a). (c) Flow cytometry analysis of the indicated CD45+ cell populations (granulocytes and 
macrophages) in the pancreas of preinvasive, classical tumours, or PDC from (a). (d) Flow cytometry analysis 
of the indicated immune cell populations (granulocytes and macrophages) in the pancreas of preinvasive, 
classical tumours, or PDC from (b). (e) Flow cytometry analysis of the indicated CD45+ cell populations (T 
cells) in the pancreas of preinvasive, classical tumours, or PDC from (a). (f) Flow cytometry analysis of the 
indicated immune cell populations (T cells) in the pancreas of preinvasive, classical tumours, or PDC from 
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(Fig. 2f). These results were corroborated by immunohistochemistry, which showed a significant reduction in the 
number of CD8+ T cells in tumours compared to preinvasive lesions (Fig. 2g). Prominent B lymphocytes infil-
tration has been previously described to occur early during pancreatic neoplasia and to exert a pro-tumorigenic 
role21. In keeping with this, we found that B lymphocytes (B220+ cells) were detectable in both early lesions and 
classical tumours while decreasing substantially in PDC (Fig. S2e,f). The T helper subset was the most abun-
dant lymphocytic population in preinvasive lesions (Fig. 2a), which prompted us to investigate whether it con-
tained immunosuppressive Treg cells22. We used immunofluorescence to co-localize Treg (Foxp3) and cytotoxic T 
cells (CD8) in tissues from different stages of disease and found that Treg cells infiltrate early, persist throughout 
tumour development, and outnumber CD8+ T cells in each stage of ODI (Fig. S2g,h,i). Overall, these data suggest 
that myeloid cells infiltrate early and persist throughout ODI progression, while T cells are excluded as tumour 
progresses. These changes in immune infiltration of the tumour were associated to specific changes in circulating 
cytokines/chemokines, with the level of G-CSF and anti-inflammatory cytokines (IL-6 and IL-10) increasing in 
PDA compared to preinvasive lesions (Figs 3a and S3). Interestingly, we also found higher circulating levels of 
IL-17 in preinvasive lesion compared to tumours (Fig. 3a). Previous studies have demonstrated that IL-17 pro-
duced by infiltrating immune cells is necessary for initiation and progression of PanIN23,24.
immunosuppression increases as tumours progress in the oDi system. T cell exclusion and T cell 
disfunction are two major mechanisms through which tumours are able to escape immune control25–27. Recent 
works have highlighted the possibility of using mRNA-based signatures as biomarkers indicative of T cell exclu-
sion/disfunction28,29. Therefore, we performed targeted gene expression profiling, using a commercially available 
NanoString panel composed of immune-related genes, in FFPE samples from preinvasive, classical and PDC 
ODIs. When comparing expression profiles (EP) from preinvasive lesions (n = 3) and classical tumours (n = 3), 
24 genes were found deregulated (adjusted p < 0.05, Supplementary Table 2). Among most upregulated genes in 
classical tumours, Nt5e, Tgfb1, and Arg1 (Figs 3b and S4a) have been consistently associated to T cell disfunc-
tion29–33. In particular, Nt5e (also known as CD73) is expressed by cancer cells and encodes for an ectonucleoti-
dase that cooperates with CD39 to generate extracellular adenosine, which can in turns prevent T cells activation 
and proliferation34. Differently from Nt5e, Arg1 is expressed by immunosuppressive myeloid cells and encodes 
a critical enzyme which converts L-arginine to urea and Lornithine. L-arginine consumption blocks the lym-
phocyte cell cycle and at the same time it promotes the blockade of the ζ chain of CD3, which prevents T cells 
from responding to various stimuli33. Among downregulated genes in classical tumours compared to preinvasive 
lesions (Figs 3b and S4a), C7 encodes for a component of the complement cascade and its reduced expression has 
been reported as a poor prognostic marker in several malignancies35,36.
When comparing EP from PDC and preinvasive lesions, 109 genes were found deregulated (adjusted p < 0.05, 
Supplementary Table 2). Upregulation of Nt5e, Tgfb1, Arg1 and downregulation of C7 was also observed in this 
comparison (Figs 3c and S4b), along with increased expression of Il4ra (Figs 3c and S4b), which encodes for the 
alpha chain of the Interleukin 4 receptor and it is a well-established marker of immunosuppressive myeloid cells37. 
Fewer genes were found deregulated when comparing EP from PDC and classical (Figs 3d and S4c), and Arg1 and 
Il4ra were among the genes further upregulated suggesting that immunosuppressive myeloid cells were accumu-
lating as tumour progressed. In addition, Muc1 was downregulated, while Fn1 and Itga5 were upregulated in PDC 
compared to classical tumours (Fig. 3d). Details about shared and unique genes up- or down-regulated compar-
ing EP from ODI at different disease stages is provided in Fig. S4e and Supplementary Table 3. Deregulation of 
selected genes (Arg1, C7, Lcn2, Nt5e, and Tgfb1) from preinvasive lesion to overt cancers (classical tumours and 
PDC) was orthogonally confirmed by qPCR (Fig. S4f).
It should be noted that while increased expression of Nt5e and Tgfb1 could be ascribed to the increase in the 
neoplastic cells content from preinvasive lesions to PDC, increased expression of immune cell genes Arg1 and 
Il4ra clearly suggest differentiation of pre-existing myeloid cells into immunosuppressive phenotypes during ODI 
progression.
ODI represents a valid biological resource for identification of clinically-relevant biomarkers. 
To assess whether interrogation of EP of ODIs at different disease stages might help identifying genes rele-
vant to the human disease, we interrogated the transcriptomes of PDA from the International Cancer Genome 
Consortium (ICGC) and The Cancer Genome Atlas (TCGA) for differential expression of selected genes (C7, 
MUC1, NT5E, TGFB1, FN1, and ITGA5) in clinically relevant subgroups. We found that mRNA expression 
of NT5E, TGFB1, FN1, and ITGA5 is enriched in aggressive subtype of PDA (squamous/basal-like) (Figs 3e,f, 
S5a,c,e,g,i,j), and that PDA having high expression of those genes showed poor prognosis in the ICGC and/or in 
the TGCA cohorts (Figs 3g, S5b,d,f,h,k). On the other hand, mRNA expression of C7 and MUC1 was downreg-
ulated in squamous/basal-like tumours (Figs 3h–i, S6c,d). Moreover, high expression of C7 and MUC1 identifies 
(b). Each dot in the graphics (c–f) refers to the individual tumour samples available for cytometric evaluation. 
ODIs from B6-K1, B6-K2, and B6-K3 organoids are identified by circles, triangles, and squares, respectively. (g) 
Immunohistochemical staining for CD8 in tissue from mice bearing preinvasive lesions (B6-K2, left), classical 
tumours (B6-K2, middle) or poorly differentiated tumours (B6-K3, right). Scale bars, 50 µm. Quantification 
is provided on the left as the average number of CD8 positive cells per mm2 in preinvasive (n = 6), classical 
(n = 10), and poorly differentiated (PDC, n = 8) tumours. From 3 to 5 individual areas per case were examined. 
Statistical associations were determined by Student’s t-test. *p < 0.05; **p < 0.01; ***p < 0.001. See also 
Supplementary Fig. 2 for details.
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Figure 3. Disease progression of organoid-derived isografts is associated with gene expression changes 
indicative of an immunosuppressive microenvironment. (a) Multiplex bead-based mouse cytokine assay for 
serum detection of circulating factors in mice bearing preinvasive lesions (n = 5), classical tumours (n = 6) 
and poorly differentiated tumours (PDC, n = 5). Mean and SEM in pg/mL are shown. See also Supplementary 
Fig. 3. (b) Volcano plots of differences in gene expression (NanoString platform) between classical tumours 
(n = 3) and preinvasive lesions (n = 3). Indicated are the genes with Log2 fold change in expression ≥ 1.5 and 
adjusted p < 0.05. (c) Volcano plots of differences in gene expression (NanoString platform) between poorly 
differentiated tumours (n = 3) and preinvasive lesions (n = 3). Indicated are the genes with Log2 fold change in 
expression ≥ 2 and adjusted p < 0.05. (d) Volcano plots of differences in gene expression (NanoString platform) 
between poorly differentiated (n = 3) and classical (n = 3) tumours. Indicated are the genes with Log2 fold 
change in expression ≥ 2 and adjusted p < 0.05. In (b,c, and d), red arrows indicate genes that are discussed 
in the text. (e,f) Box plot showing the NT5E Z-score score stratified by Bailey (e) or Moffitt subtypes (f) in the 
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PDA patients that tended to have better prognosis (Figs 3k, S6b,e). These results demonstrate that the ODIs can 
be used a biological resource for the identification of genes associated to the progression of PDA.
M2 macrophages accumulate during progression of disease. In addition to the expression of genes 
known to be associated to T cell disfunction, we also used mRNA profiles from ODI to explore cell signatures 
associated to T cell exclusion. Reduced intratumoural T cell infiltration can be due to presence of immunosup-
pressive population or lack of T cell priming25,26.
First, we explored gene signatures of antigen presentation and processing and found that only reduction of 
a B cells signature, in the comparison classical tumours vs preinvasive lesions, had a trend towards significance 
(p = 0.081) (Fig. 4a). This suggests that same mechanisms are likely operating very early in preinvasive lesions and 
persist throughout tumour development.
We then used expression profiles to examine two major populations known to reduce intratumoural T cell 
infiltration, namely granulocytic myeloid-derived suppressor cells (g-MDSC) and anti-inflammatory (M2) 
macrophages.
By flow-cytometric analysis we have already showed that granulocytes and macrophages were present as early 
as in PanIN-like lesions and persisted in established tumours without further expansion. Expression profiles 
and cell-type specific signatures (Supplementary Table 4) were used to evaluate whether signatures of immu-
nosuppressive granulocytes and/or macrophages were enriched in advanced stages of ODI. We found a signifi-
cant increase in signatures associated to immunosuppressive macrophages during progression from preinvasive 
lesions to invasive carcinomas (p = 0.01, Fig. 4b). To corroborate this finding, we orthogonally validated the 
increase in M2 during tumour progression in ODI by immunohistochemistry using a known marker of M2 
macrophages, the transcription factor Maf (Fig. S7a)32,38,39. Immunohistochemical staining for Maf confirmed 
that M2 macrophages accumulated during progression in ODI (Fig. 4c,d) and inversely correlated to infiltration 
of CD8+ T cells (Fig. 4e,f).
MAf expressing macrophages accumulates during progression of human pDA. To translate our 
results in the human disease, we first sought to assess the expression of MAF in relation to PDA subtypes and 
found that MAF is enriched in the subtypes dominated by macrophage signatures (Immunogenic and Squamous/
basal-like) in the TCGA cohort and in the Squamous subtype in the ICGC cohort (Figs 5a and S7b)6. In the PDA 
cohort of the ICGC, patients with high expression of MAF has worst prognosis (Fig. 5b), and patients with high 
expression of MAF and low level of a signature of tumour-infiltrating lymphocytes had worst prognosis in the 
TCGA cohort (Fig. 5c). We then evaluated whether M2 macrophages were accumulating during progression in 
human tissues. Therefore, we selected 6 preinvasive lesions (2 PanINs and 4 IPMNs), 11 well-to-moderately dif-
ferentiated PDA, and 11 tumours defined as squamous/Poorly differentiated based on the expression of known 
squamous cell markers, namely CK5 and p6340 (Fig. S7c). Consistently with observations in ODIs, macrophages 
expressing MAF were enriched in tumours compared to preinvasive lesions (Fig. 5d,e), although no statistically 
significant difference was observed between classical tumours and poorly differentiated tumours.
Discussion
Increasing evidence suggests that cancer cell programs driven by specific genetic events dictate the immune con-
texture of PDA6,14. However, recent studies conducted in GEMM have demonstrated that the selective targeting of 
myeloid cell populations influence gene expression programs of cancer cells11,12. It is becoming clear that the abil-
ity of conducting integrative and dynamic genotypic-immunophenotypic analyses is a fundamental requirement 
for the identification of undisclosed therapeutic strategies that effectively elicit anti-tumour immunity. Here, we 
tracked the immunoevolution of PDA in a genetically-defined and transplantable model of mouse pancreatic 
tumour organoids that recapitulates the progression of the disease from early preinvasive lesions to metastatic 
carcinomas. We demonstrated that leukocytes heavily infiltrated the pancreas as early as in preinvasive lesion, 
which is in line with previous observation in autochthonous model of the disease15. Myeloid cells, and in particu-
lar granulocytes, were the most represented immune subpopulation in preinvasive lesions, which outnumbered 
lymphocytes during progression. We showed that the expansion of granulocytes within the tumour-infiltrating 
leukocytes compartment was accompanied by increased level of serum G-CSF and dramatic decrease of T cell 
infiltration, which suggest mechanisms of T cell exclusion. However, it should be noted that the absolute number 
of infiltrating CD8+ T cells was scarce even in preinvasive lesions. Progression from preinvasive lesions to overt 
cancers was also associated to increased expression of potent immunosuppressive genes, among which Nt5e and 
Tgfβ1 have been previously shown to induce T cell dysfunction29–31,34. Notably, we found that the expression 
of the two genes was enriched in aggressive subtype of PDA and negatively correlated with patients’ survival. 
Along with the identification of C7 and MUC1, whose high expression indicated better survival, our data demon-
strates that the ODI can be used a biological resource for the identification of clinically-relevant biomarkers in 
PDA. In line with previous observation15, we also found that macrophages were present at preinvasive stage and 
persisted throughout PDA. However, we found a significant expansion of M2 macrophages during progression 
ICGC cohort. ****p ≪ 0.001; ***p < 0.001; *p < 0.05 as determined by Wilcoxon rank-sum test. (g) Kaplan–
Meier analysis comparing survival of patients in the ICGC cohort having either high or low expression of NT5E. 
p, Log-rank (Mantel-Cox) test. (h,i) Box plot showing the C7 Z-score score stratified by Bailey (h) or Moffitt 
subtypes (i) in the ICGC-PDA cohort. ****p ≪ 0.001; *p < 0.01 as determined by Wilcoxon rank-sum test. (j) 
Kaplan–Meier analysis comparing survival of patients in the ICGC cohort having either high or low expression 
of C7. p, Log-rank (Mantel-Cox) test. See also Supplementary Figs 5 and 6.
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of the disease. Polarization of macrophages towards M2 phenotype is supported by an immunosuppressive 
cytokine milieu composed of tumour- and stromal-derived factors that include TGFβ, IL-6 and IL-1032,41–43. 
Consistently, we found elevated serum level of IL-6 and IL-10 as lesions progressed over time. MAF expressing 
M2 macrophages accumulated during progression and inversely correlated with infiltration of CD8+ T cells in 
mouse tumours, suggesting that they might be the prominent immune cell type to mediate T cell exclusion. We 
confirmed that expression of MAF is higher in PDA subtypes dominated by macrophage-related signatures, in 
particular in the squamous subtype, and negatively correlated with patients’ survival in the ICGC cohort. Among 
PDA tumours of the TCGA cohort, low TILs levels indicated a worse patients’ survival but only when MAF had 
lower expression, which is in line with the antagonist interaction between Maf+ macrophages and CD8+ T cells 
that we found in ODI. Although we only looked at few cases, density of MAF expressing macrophages was sig-
nificantly higher in human PDA tissues compared to preinvasive lesions, which included PanINs and IPMNs. Of 
the common PDA drivers, mutations Kras and Trp53 were the only detectable oncogenic events across lesions 
Figure 4. MAF positive macrophages accumulate during progression of ODI. (a,b) Box plots of signature 
scores in organoid derived isografts stratified according to the stage of disease. p values, Wilcoxon rank-sum 
test. Please refer to Supplementary Table 4 for details on genes used to define the specific gene signatures. 
(c) Immunohistochemical staining for Maf in tissues from mice bearing preinvasive lesions (left), classical 
tumours (middle), or poorly differentiated tumours (right). All tissues derive from B6-K3 organoid transplants. 
Scale bars, 100 µm. Quantification is provided in (d) as the average number of Maf positive nuclei per mm2 in 
preinvasive (n = 6), classical tumours (n = 10), and PDC (n = 7). From 3 to 5 individual areas per case were 
examined. Statistical associations were determined by Student’s t-test. *p < 0.05; ***p < 0.001. (e) Correlation 
between number of MAF positive and CD8 positive cells in mouse tumours considering all stages of disease 
(a total of 40 individual areas of 1 mm2 were considered) (Spearman r = −0.50, p = 0.010). Shown is the curve 
of linear fit correlation. (f) Immunofluorescence analysis for MAF (red) and CD8 (green), in mouse classical 
tumour tissues indicated as red or green circles in (e). Nuclei were counterstained with DAPI (blue). Scale bar, 
20 µm. TREG, regulatory T cells; CTLs. Cytotoxic T lymphocytes; M2, anti-inflammatory macrophages; AP, 
antigen presentation; DC, dendritic cells; gMDSC, granulocytic-myeloid derived suppressor cells.
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at different stages of the disease with the exception of the LOH affecting Trp53 in poorly-differentiated and met-
astatic tumours. However, considering that we only looked at a limited genomic space (19 commonly mutated 
genes in PDA and peripancreatic tumours), we cannot rule out the possibility that progression of this model 
Figure 5. MAF is overexpressed in the aggressive subtype of PDA. (a) Box plot showing the MAF Z-score 
score stratified by Bailey subtypes in the ICGC-(left) and TCGA (right) cohorts. ***p < 0.001; **p < 0.01; 
*p < 0.05 as determined by Wilcoxon rank-sum test. (b) Kaplan–Meier analysis comparing survival of patients 
in the ICGC cohort having high, intermediate or low expression of MAF. p, Log-rank (Mantel-Cox) test. (c) 
The association between the CTL level and overall patient survival for PDA tumours with different MAF levels. 
For each tumour in the TCGA, the infiltration of cytotoxic T lymphocytes or Tumour-infiltrating lymphocytes 
(TILs) was estimated as the average expression level of GZMB, GZMA, PRF1, and CD8A. Kaplan–Meier 
analysis compares the survival of patients with low TILs and high expression. p, Log-rank (Mantel-Cox) test.  
(d) Immunohistochemical staining for MAF in human tissues distinguished in preinvasive lesions (left), 
classical tumours (middle), or poorly differentiated tumours (right). Scale bars, 100 µm. Quantification is 
provided in (e) as the average number of MAF positive nuclei per mm2 in preinvasive (n = 6), classical tumours 
(n = 11), and poorly differentiated carcinomas (PDC, n = 11). From 5 to 6 individual areas were examined per 
case. Statistical associations were determined by Student’s t-test. *p < 0.05; **p < 0.01.
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is associated with accumulation of other genomic events. Mouse organoids can be genetically manipulated ex 
vivo, which provides the potential of creating models for interrogating effects of specific genotypes on immune 
contexture of PDA. Overall, our results show that, in ODI, progression of disease is associated to an increased 
immunosuppressive microenvironment that outweighs antitumour cellular immunity, thereby likely contributing 
to disease progression. We also showed that MAF expressing macrophages are prominent myeloid cells popula-
tion in both mouse and human PDA, which warrants future investigation for potential therapeutic intervention.
Materials and Methods
patients’ samples. Pancreatic cancer tissues were obtained from patients undergoing surgical resection at 
the University Hospital Trust of Verona. Ethics committee approval was obtained at University of Verona, Italy: 
approval number 1885 from the Integrated University Hospital Trust (AOUI) Ethics Committee (Comitato Etico 
Azienda Ospedaliera Universitaria Integrata). Written informed consent from the donors for research use of tis-
sue in this study was obtained prior to acquisition of the specimen. Samples were confirmed to be tumour or nor-
mal based on pathological assessment. All experiments were conducted in accordance with relevant guidelines 
and regulations. Human formalin-fixed paraffin-embedded (FFPE) tissues were used for immunohistochemical 
staining. A total of 28 tissue specimens were used, including: 6 preinvasive lesions (2 PanINs and 4 IPMNs), 11 
well differentiated PDA (defined as “classical”), 11 squamous/poorly differentiated tumours.
Mice. Trp53+/LSL-R172H, Kras+/LSL-G12D and Pdx1-Cre strains on a C57Bl/6 background were interbred to obtain 
Pdx1-Cre; Kras+/LSL-G12D; Trp53+/LSL-R172H (KPC) mice16. Six- to 8-weeks old C57Bl/6 J (B6J) mice were purchased 
from Charles River Laboratory. All animal experiments were conducted in accordance with procedures approved 
by CIRSAL at University of Verona (approved project 655/2017-PR).
Mouse pancreatic ductal organoid culture. Mouse pancreatic tumour cells were isolated from the 
tumour bulk of mice older than 8 weeks as previous described17,19. Briefly, mouse pancreatic tumours were minced 
and digested by enzymatic dissociation with 5 mg/ml Collagenase type XI (Gibco), 1 mg/ml Dispase (Gibco), 1% 
FBS (Gibco) in DMEM medium (Gibco) at 37 °C for a maximum of 16 hrs. Isolated material was incubated with 
TrypLE (Gibco) at 37 °C for 10 min, embedded into growth factor-reduced Matrigel (Corning), and cultured in 
mouse complete medium (AdDMEM/F12 (Gibco) supplemented with 1% penicillin/streptomycin (Gibco), 1% 
GlutaMAX (Gibco), 10 mM HEPES (Gibco), 1:50 B27 supplement (Gibco), 1.25 mM N-Acetylcysteine (Sigma), 
10% (vol/vol) Rspo1-conditioned media, 10 mM Nicotinamide (Sigma), 10 nM recombinant human-gastrin I 
(Tocris), 50 ng/ml recombinant mouse EGF (Gibco), 100 ng/ml recombinant human FGF10 (Peprotech), 0.5 µM 
A83-01 (Tocris), and 100 ng/ml recombinant human Noggin (Peprotech)). Mouse complete medium was changed 
twice a week, and cultures were split upon the attainment of dense culture. Passage was performed in a 1:4–1:8 
split ratio.
targeting sequencing. High-coverage sequencing of organoid cultures and tissues from organoid trans-
plants was performed using an AmpliSeq custom panel (ThermoFisher) targeting all exons of 19 genes fre-
quently mutated in pancreatic and peripancreatic tumours (detailed list of genes in Supplementary Table 1). For 
each reaction, 20 ng of DNA were used, and the quality of the resulting libraries evaluated by the Agilent 2100 
Bioanalyzer on-chip electrophoresis (Agilent Technologies). Sequencing runs were performed on the Ion Proton 
(PI, ThermoFisher) loaded with Ion PI Chip v2. Base calling, alignment to the mm10 mouse reference genome, 
and variant calling were done using the Torrent Suite Software v.5.0 (ThermoFisher). Alignments were visually 
verified with the Integrative Genomics Viewer (IGV)44. Targeted sequencing data were also used to estimate loss 
of heterozygosity (LOH).
pancreatic organoid transplantation. For the orthotopic transplantation of mouse organoids, recipient 
mice were anesthetized with isoflurane. Organoids (1 × 106 cells/mouse) were recovered from Matrigel using 
ice-cold Cell Recovery Solution (Corning) for 30 min, and then mechanically dissociated into small fragments 
through fire-polished glass pasteur pipettes. Before transplantation, organoids were resuspended in 50 µl of a 
2:3 dilution of Matrigel and cold PBS. An incision was made in the left abdominal side at the level of the spleen. 
Organoids were injected into the tail region of the pancreas using insulin syringes (BD micro-fine 30 G). The 
injection was considered successful by the development of bubble without signs of leakage. The peritoneum was 
sutured with short-term absorbable suture (Vetsuture), and the skin was closed with wound clips (CellPoint 
Scientific Inc.). Mice were sacrificed at the indicated time points. Monitoring of tumour growth was performed 
as previously described18. Briefly, following weekly manual palpation starting 10 days following transplantation, 
tumour-bearing mice were subjected to high-contrast ultrasound screening using the Vevo 2100 System with a 
MS250, 13–24 MHz scanhead (Visual Sonics, Inc, Amsterdam, NL).
flow cytometry. The tumour flow cytometry-based immuno phenotype was performed according to 
already published protocols45. Briefly, tumours were minced and digested for about 1 hr at 37 °C under contin-
uous mixing with a digestive mix containing 1 mg/mL collagenase IV, 0.1 mg/mL hyaluronidase, and 30 U/mL 
DNAse in RPMI 1640, all purchased from Sigma-Aldrich. The cell suspension was separated from the undi-
gested material using a 70-μm cell strainer (Corning). On the contrary, the analysis of circulating leukocytes was 
performed using splenocytes collected by mechanical disruption of the tissue followed by red blood cell lysis 
with the ACK buffer (Lonza). One million of cells were incubated with anti-mouse CD16/32 (Biolegend) and 
subsequently stained with the following antibodies according to the vendor’s instructions: CD3 (17A2, Thermo 
Fisher Scientific), CD4 (GK1.5, Thermo Fisher Scientific), CD8a (53.6.7, Thermo Fisher Scientific), F4/80 (A3-
1, Bio-Rad), MHC2 (M5/114.15.2, Thermo Fisher Scientific), CD11b (M1/70, Thermo Fisher Scientific), B220 
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(RA3-6B2, Thermo Fisher Scientific) CD11c (N418, Thermo Fisher Scientific), LY6C (HK1.4, Biolegend), LY6G 
(1A8, Biolegend), CD45 (30F11, Biolegend), Samples were acquired on a FACS Canto II (BD Biosciences) and 
analyzed with FlowJo software (FlowJo LLC).
Histology and immunohistochemistry. Tissues were fixed in 10% neutral buffered formalin and embed-
ded in paraffin. Sections were subjected to Hematoxylin and Eosin, and Masson’s Trichrome staining as well as 
immunohistochemical staining. The following primary antibodies were used for immunohistochemical staining 
and established procedures46: F4/80 (ab6640, Abcam), 1:100; MAF (sc-7866, clone M-153, Santa Cruz) 1:200; 
CD8 (14-0808-82, Thermo Scientific) 1:2000; CD206 (ab64693, Abcam) 1: 200; CK5 (XM26, Novocastra) 1:100; 
p63 (DAK p63, DAKO) 1:50. Staining quantification was performed using ImageJ. For immunofluorescence 
staining, paraffin slides were deparaffinized and subjected to antigen retrieval using citric acid buffer (pH 6). 
Primary antibodies (1:200 MAF; 1:750 CD8) were then applied overnight at 4 °C, and then revealed by incubation 
with secondary antibodies conjugated to fluorophores. To reduce background nonspecific staining, slides were 
immersed in 0.1% Sudan Black B (Carlo Erba) in 70% ethanol for 20 min, and then washed with PBS. Nuclei were 
stained with DAPI (Sigma). Images were captured on a Zeiss AxioObserver Z1 inverted fluorescence microscope 
(Zeiss).
For multiplex immunofluorescence staining, we used the Opal Multiplex IHC Kit (Akoya) and the follow-
ing antibodies: CD8α (98941, Cell Signaling) 1:100; FoxP3 (12653, Cell Signaling) 1:100. Briefly, FFPE sections 
were deparaffinized and then subjected to several sequential of microwave treatment and staining. Each includes 
antigen retrieval by heat-induced epitope retrieval using citrate buffer (pH6), a protein blocking followed by 
primary antibody, introduction of Secondary-HRP, and incubation with Opal Fluorophore for 10 min at room 
temperature. After all sequential staining reactions, sections were counterstained with DAPI (Vector lab). Slides 
were scanned by Leica TCS SP5 laser scanning confocal (Leica) with 80 × objective magnification and digitalized 
by the Leica Application Suite X (LAS X) software. Immunofluorescence images were quantified using five fields 
per tumour.
Multiplex cytokines profiling. Mouse plasma specimens were analyzed using a mouse multiplex ELISA 
kit according to the manufacturer instructions (Bio-Rad Laboratories, Hercules, California, U.S.A.). All samples 
were tested for the expression of circulating interleukin (IL)1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-9, IL-12p40, 
IL-12p70, IL-13, CCL11 (eotaxin), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon 
(IFN)γ, monocyte chemoattractant protein (MCP-1; CCL2), macrophage inflammatory protein 1α (MIP-1α; 
CCL3), macrophage inflammatory protein 1β (MIP-1β; CCL4), CCL5 (RANTES), CXCL1 (KC), tumour necro-
sis factor (TNF)α. Median fluorescence intensities were collected on a Bio-Plex 200 instrument, using Bio-Plex 
Manager software version 6.2. Standard curves for each cytokine were generated using the premixed lyophilized 
standards provided in the kits. Median fluorescent intensities were transformed into cytokines concentrations by 
5-point-regression.
mRNA profiling and qRT-PCR. Total RNA was extracted from formalin fixed paraffin embedded (FFPE) 
tissues using the RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE (ThermoFisher). A concentration of at 
least 10 ng/μl was achieved for each sample. Purity of RNA was suitable when A260/A280 ratio was over 1.7 and 
A260/A230 ratio was over 1.8. Expression analysis was performed using Nanostring Mouse PanCancer Immune 
Profiling Kit (Diatech XT-CSO-MIP1-12). For FFPE tissues 150 ng of RNA was used according to the manu-
facturer’s protocol. The matrix of genes counts was then used for differential expression analysis with DESeq2 
Bioconductor package47. DESeq2 was used in combination with RUVSeq48 in order to control housekeeping genes 
expression and for normalization purposes. A batch factor of variation was calculated from the expression of the 
housekeeping genes, and such factor was then added to the DESeq2 design formula. Gene set variant analysis was 
performed with the GSVA Bioconductor package with the following parameters: method = ‘gsva’, mx.diff = TRUE, 
kcdf = ‘Gaussian’49. The list of gene sets used, and associated references is available in the Supplementary Table 4.
For qPCR analyses, 500 ng of total RNA was reverse transcribed using SuperScript® VILOTM cDNA Synthesis 
Kit (Life Technologies) in a volume of 20 µl according to the manufactures’ instructions. Samples were diluted 
to a final concentration of 10 ng/µl. TaqMan was performed in triplicate using 20 ng of cDNA and the following 
TaqMan® probe (TaqMan® Gene Expression Assay): Nt5e (Mm00501910_m1); Arg1 (Mm00475988_m1); Tgfb1 
(Mm01178820_m1); C7 (Mm01297045_m1); and Lcn2 (Mm01324470_m1). Hprt1 was used as reference gene. 
Relative gene expression quantification was performed using the ΔΔCt method with the Sequence Detection 
Systems Software, Version 1.9.1 (Applied Biosystems).
Data mining. For data mining and pancreatic cancer subtypes stratifications we used two different data-
sets. The first dataset represents the PACA-AU cohort of the ICGC consortium, downloaded from the supple-
mental material of the corresponding publication6. This dataset contains normalized expression values (TMM 
normalized using edgeR Bioconductor package, converted to CPM and log2 transformed) of 96 pancreatic 
cancer patients; for subtypes stratification, z-scores were calculated for each gene. Associated clinical data were 
downloaded from https://dcc.icgc.org/releases/current/Projects/PACA-AU. The second dataset represents the 
TCGA-PAAD cohort, downloaded from http://firebrowse.org/?cohort = PAAD, which consists of the RNA-Seq 
gene expression profile of 178 pancreatic cancer patients. According to other publications that disputed the purity 
of some samples, we restricted the number to 148 assured samples. The grouping of the samples in Bailey’s and 
Moffitt’s subtypes7 was performed with the GSVA Bioconductor package with the same options as above. The gene 
sets used for the stratification were retrieved from the original publications.
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Statistical analysis. Differences between experimental conditions were tested using Student’s t-test or 
Wilcoxon rank-sum test, according to the normality of samples’ distribution verified with a Shapiro-Wilk test. 
A p-value < 0.05 was considered statistically significant. Spearman’s rho correlation coefficient method was used 
to assess correlation between two variables. Survival analyses were performed using the computing environment 
R50 and the packages survival51, for fitting the model, and survminer52 for plotting. Overall survival data were 
obtained from the same link reported above. Median survival was estimated with the Kaplan-Meier method and 
the difference was tested using the log-rank (Mantel-Cox) test. For stratifying survival, gene expression data were 
divided into quartiles.
Data Availability
Supporting data and protocols are made available without restrictions.
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